Equillium provides timing update on conference presentations

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced timing updates for two separate conference presentations. equillium will now participate in a virtual fireside chat presentation at the svb leerink virtual global healthcare conference on thursday, february 17, 2022, at 2:20 pm eastern time. a live webcast of the presentat
EQ Ratings Summary
EQ Quant Ranking